OBJECTIVE: To compare the longitudinal changes in total bone mineral density (TBMD) across antiretroviral (ARV) regimens. METHODS: A5142 was an open-label study comparing 3 ARV regimens for the initial treatment of HIV-1. Subjects were randomized equally to efavirenz (EFV) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs), lopinavir/ritonavir (LPV/r) plus 2 NRTIs, or LPV/r plus EFV without NRTI. The NRTI regimen (lamivudine [3TC] plus zidovudine [ZDV], stavudine [d4T], or tenofovir [TDF]) was selected prior to randomization. TBMD was assessed via whole-body dual-energy X-ray absorptiometry (DXA) at baseline and 48 and 96 weeks. Analysis was modified intent-to-treat (ITT) ignoring regimen changes using all evaluations. RESULTS: Significant mean declines in TBMD at week 48 were observed among subjects. In repeated-measures analysis of changes (including randomized regimen, NRTI used, and time), there was a significant difference in the NRTI-containing arms in mean percentage change in TBMD at week 48 according to NRTI used (P < .001). Subjects taking ZDV had similar changes to those taking d4T (P = .970), whereas those taking TDF had larger declines (P < .001). There was a nonsignificant trend toward greater mean declines among subjects taking LPV/r versus EFV (P = .080). Overall, TDF-containing regimens demonstrated the greatest losses in TBMD, while EFV regimens without TDF had lesser TBMD reductions even compared to the NRTI-sparing arm. From week 48 to 96, all treatment groups continued to lose TBMD at similar rates. CONCLUSIONS: Among NRTI-containing arms, NRTI selection, especially use of TDF, had a greater effect on TBMD change than randomized regimen. The long-term clinical significance remains to be demonstrated.
RCT Entities:
OBJECTIVE: To compare the longitudinal changes in total bone mineral density (TBMD) across antiretroviral (ARV) regimens. METHODS: A5142 was an open-label study comparing 3 ARV regimens for the initial treatment of HIV-1. Subjects were randomized equally to efavirenz (EFV) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs), lopinavir/ritonavir (LPV/r) plus 2 NRTIs, or LPV/r plus EFV without NRTI. The NRTI regimen (lamivudine [3TC] plus zidovudine [ZDV], stavudine [d4T], or tenofovir [TDF]) was selected prior to randomization. TBMD was assessed via whole-body dual-energy X-ray absorptiometry (DXA) at baseline and 48 and 96 weeks. Analysis was modified intent-to-treat (ITT) ignoring regimen changes using all evaluations. RESULTS: Significant mean declines in TBMD at week 48 were observed among subjects. In repeated-measures analysis of changes (including randomized regimen, NRTI used, and time), there was a significant difference in the NRTI-containing arms in mean percentage change in TBMD at week 48 according to NRTI used (P < .001). Subjects taking ZDV had similar changes to those taking d4T (P = .970), whereas those taking TDF had larger declines (P < .001). There was a nonsignificant trend toward greater mean declines among subjects taking LPV/r versus EFV (P = .080). Overall, TDF-containing regimens demonstrated the greatest losses in TBMD, while EFV regimens without TDF had lesser TBMD reductions even compared to the NRTI-sparing arm. From week 48 to 96, all treatment groups continued to lose TBMD at similar rates. CONCLUSIONS: Among NRTI-containing arms, NRTI selection, especially use of TDF, had a greater effect on TBMD change than randomized regimen. The long-term clinical significance remains to be demonstrated.
Entities:
Keywords:
HIV; antiretroviral therapy; bone density
Authors: Babafemi Taiwo; Lu Zheng; Sebastien Gallien; Roy M Matining; Daniel R Kuritzkes; Cara C Wilson; Baiba I Berzins; Edward P Acosta; Barbara Bastow; Peter S Kim; Joseph J Eron Journal: AIDS Date: 2011-11-13 Impact factor: 4.177
Authors: Richard H Haubrich; Sharon A Riddler; A Gregory DiRienzo; Lauren Komarow; William G Powderly; Karin Klingman; Kevin W Garren; David L Butcher; James F Rooney; David W Haas; John W Mellors; Diane V Havlir Journal: AIDS Date: 2009-06-01 Impact factor: 4.177
Authors: J D Lundgren; M Battegay; G Behrens; S De Wit; G Guaraldi; C Katlama; E Martinez; D Nair; W G Powderly; P Reiss; J Sutinen; A Vigano Journal: HIV Med Date: 2008-02 Impact factor: 3.180
Authors: Iwen F Grigsby; Lan Pham; Louis M Mansky; Raj Gopalakrishnan; Kim C Mansky Journal: Ther Clin Risk Manag Date: 2010-02-02 Impact factor: 2.423
Authors: Todd T Brown; Grace A McComsey; Martin S King; Roula B Qaqish; Barry M Bernstein; Barbara A da Silva Journal: J Acquir Immune Defic Syndr Date: 2009-08-15 Impact factor: 3.771
Authors: Philip M Grant; Douglas Kitch; Grace A McComsey; Michael P Dube; Richard Haubrich; Jeannie Huang; Sharon Riddler; Pablo Tebas; Andrew R Zolopa; Ann C Collier; Todd T Brown Journal: Clin Infect Dis Date: 2013-08-13 Impact factor: 9.079
Authors: Julie J Kim-Chang; Lorena Wilson; Cliburn Chan; Bernard Fischer; Guglielmo Venturi; Maureen M Goodenow; Grace Aldrovandi; Thomas J Weber; John W Sleasman Journal: AIDS Res Hum Retroviruses Date: 2019-06-27 Impact factor: 2.205
Authors: Grace A McComsey; Douglas Kitch; Eric S Daar; Camlin Tierney; Nasreen C Jahed; Pablo Tebas; Laurie Myers; Kathleen Melbourne; Belinda Ha; Paul E Sax Journal: J Infect Dis Date: 2011-06-15 Impact factor: 5.226
Authors: Babafemi O Taiwo; Ellen S Chan; Carl J Fichtenbaum; Heather Ribaudo; Athe Tsibris; Karin L Klingman; Joseph J Eron; Baiba Berzins; Kevin Robertson; Alan Landay; Igho Ofotokun; Todd Brown Journal: Clin Infect Dis Date: 2015-06-09 Impact factor: 9.079
Authors: James M Mikula; Maura M Manion; Frank Maldarelli; Lucila M Suarez; Jaha F Norman-Wheeler; Alex G Ober; Robin L Dewar; Jeffrey B Kopp; H Clifford Lane; Alice K Pau Journal: Antivir Ther Date: 2016-03-08